drugset / Trial / NCT00488124

Growth Response in Short Children Suffering From a Disease With Growth Retardation and Treated With Somatropin

NCT00488124

Phase 2 Completed 120 enrolled University of Erlangen-Nürnberg Medical School
NaSingle-groupOpen-labelTreatment

Summary

Growth hormone therapy will improve the height of short statured children with pathological conditions that lead to growth retardation. Growth hormone therapy will show an increase in height velocity \>1 SD compared to pretreatment height velocity. and the therapy will be safe.

Timeline

Start
2005-11
Primary completion
2011-02
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatropin Protein / enzyme biologic 0.035 mg/kg Subcutaneous